Cancer cells adjusted to have normal circadian rhythm slowed tumor growth.
Hematology
Latest News
Advertisement
CME Content
Advertisement
Tumor growth can be fueled by sleep disruption.
Extrachromosomal oncogene helps drive tumor evolution and heterogeneity.
Lenalidomide (Revlimid) maintenance improved survival in multiple myeloma patients following a stem cell transplant.
Revlimid is the only FDA-approved maintenance therapy for multiple myeloma following stem cell transplant.
Inotuzumab ozogamicin treats relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Inotuzumab ozogamicin was granted priority review in patients with acute lymphoblastic leukemia.
The FDA has accepted Pfizer’s biologics license application (BLA) and granted priority review for their experimental leukemia treatment.
Top news of the week in oncology and cancer drug development.
Certain BRCA1 mutations reduce the risk of developing leukemia.
Unreliable data found in reports that did not support the professor’s hypothesis in cancer research.
Top news of the week in oncology and cancer drug development.
Yeast-derived L-asparaginase seen to be less toxic than an enzyme derived from bacteria.
Top news of the week in oncology and cancer drug development.
Poor long-term survival rates for pediatric patients with acute megakaryoblastic leukemia.
Top news of the week in oncology and cancer drug development.
Top news of the week in oncology and cancer drug development.
Top news of the week in oncology and cancer drug development.
Combination therapy to be assessed in multiple myeloma and solid cancers.
Opdivo plus Darzalex will be investigated in a new clinical trial.
Top news of the week in oncology and cancer drug development.
Multiple clinical trials of vadastuximab talirine have been placed on clinical hold by the FDA.
ASN003 demonstrated potent action against tumor growth.
Hispanic newborns that develop acute lymphoblastic leukemia are 5.9% times more likely to have a cytomegalovirus infection at birth.
Cancer accounts for more years of life lost than any other cause of death.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
2
Study Finds Similar Outcomes Between hMPV and RSV Hospitalizations
3
Higher Ultra-Processed Food Intake Linked to Increased Prediabetes Risk in Young Adults
4
Late-Breaking Data Support Lorundrostat Treatment in Patients With CKD
5
